SecurityHCM / Hutchison China MediTech Limited (44842L103)
Institutional Owners39
Institutional Shares55,260,625
Institutional Value$ 1,011,115,000 USD
Related HNCMF / Hutchison China Meditech Ltd.

Institutional Stock Ownership and Shareholders

Hutchison China MediTech Limited (NASDAQ:HCM) has 39 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 55,260,625 shares. Largest shareholders include CK Hutchison Holdings Ltd, Prudential Plc, Mitsui & Co Ltd, Oppenheimer Funds Inc, Karst Peak Capital Ltd, JP Morgan Chase & Co, Schroder Investment Management Group, Wellington Management Group LLP, Bellevue Group AG, and Allianz Asset Management AG.
Hutchison China MediTech Limited (NASDAQ:HCM) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 27,087 27,639 2.04 801 834 4.12
2018-08-14 13F-HR MORGAN STANLEY 11,329 17,849 57.55 334 538 61.08
2018-08-01 13F-HR Sumitomo Mitsui Trust Holdings, Inc. 108,085 121,430 12.35 3,195 3,660 14.55
2018-08-14 13F-HR Prince Street Capital Management LLC 81,400 81,400 0.00 2,406 2,453 1.95
2018-05-11 13F-HR HSBC HOLDINGS PLC 64,753 0 -100.00 2,553 0 -100.00
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 3,594 3,067 -14.66 106 92 -13.21
2018-08-09 13F-HR GSA CAPITAL PARTNERS LLP 201,268 222,345 10.47 5,949 6,701 12.64
2018-08-13 13F-HR PIONEER INVESTMENT MANAGEMENT INC 54,599 54,599 0.00 1,614 1,645 1.92
2018-08-14 13F-HR UBS Group AG 2,612 431 -83.50 78 13 -83.33
2018-08-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 45,617 110,534 142.31 1,348 3,332 147.18
2018-08-15 13F-HR CASTLEARK MANAGEMENT LLC 4,500 0 -100.00 133 0 -100.00
2018-08-14 13F-HR MARSHALL WACE ASIA Ltd 10,620 320
2018-07-30 13F-HR State of New Jersey Common Pension Fund D 87,945 2,651
2018-08-13 13F-HR Allianz Asset Management AG 237,973 303,729 27.63 7,034 9,154 30.14
2018-07-17 13F-HR BAILLIE GIFFORD & CO 206,140 204,663 -0.72 6,093 6,169 1.25
2018-08-14 13F-HR PRUDENTIAL PLC 3,897,456 4,112,096 5.51 115,209 123,939 7.58
2018-07-13 13F-HR MCKINLEY CAPITAL MANAGEMENT LLC /DELAWARE 24,238 23,222 -4.19 717 700 -2.37
2018-08-13 13F-HR Renaissance Technologies LLC 149,800 4,428
2018-08-14 13F-HR ROYAL BANK OF CANADA 6,747 203 -96.99 199 6 -96.98
2018-08-14 13F-HR Folger Hill Asset Management LP 42,772 43,840 2.50 1,264 1,321 4.51
2018-08-14 13F-HR Tower Research Capital LLC (TRC) 200 0 -100.00 6 0 -100.00
2018-08-13 13F-HR Hudson Bay Capital Management LP 17,200 17,200 0.00 508 518 1.97
2018-08-07 13F-HR Bellevue Group AG 302,420 332,536 9.96 8,940 10,023 12.11
2018-08-13 13F-HR Advisor Group, Inc. 352 293 -16.76 10 9 -10.00
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 0 14,196 0 427
2018-08-13 13F-HR OPPENHEIMER FUNDS INC 1,684,770 2,972,947 76.46 49,802 89,604 79.92
2018-08-14 13F-HR DekaBank Deutsche Girozentrale 30,000 27,000 -10.00 866 826 -4.62
2018-08-14 13F-HR PERCEPTIVE ADVISORS LLC 10,000 10,000 0.00 296 301 1.69
2017-02-08 SC 13G CK Hutchison Holdings Ltd 36,666,667
2018-07-18 13F-HR Bt Investment Management Ltd 16,936 18,166 7.26 500,628 547,523 9.37
2017-02-13 SC 13G MITSUI & CO LTD 3,214,404
2018-08-23 13F-HR/A SCHRODER INVESTMENT MANAGEMENT GROUP 1,281,443 1,515,640 18.28 37,879 46,348 22.36
2018-08-14 13F-HR Karst Peak Capital Ltd 2,005,580 1,842,311 -8.14 59,285 55,527 -6.34
2018-08-02 13F-HR/A ALPS ADVISORS INC 191,933 5,785
2018-08-03 13F-HR Harvest Fund Management Co., Ltd 164,184 0 -100.00 4,852 0 -100.00
2018-08-14 13F-HR Wellington Management Group LLP 580,527 1,172,897 102.04 17,161 35,350 105.99
2018-08-14 13F-HR JP Morgan Chase & Co 1,527,742 1,585,723 3.80 45,159 47,794 5.83
2018-08-14 13F-HR AQR CAPITAL MANAGEMENT LLC 48,809 0 -100.00 1,443 0 -100.00
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 9,674 7,029 -27.34 286 212 -25.87
2018-08-13 13F-HR INDUS CAPITAL PARTNERS, LLC 24,800 24,800 0.00 733 747 1.91
2018-08-14 13F-HR DEUTSCHE BANK AG\ 64,233 800 -98.75 1,898 24 -98.74
2018-08-14 13F-HR Jabre Capital Partners S.A. 39,087 37,058 -5.19 1,155 1,117 -3.29
2018-08-14 13F-HR MILLENNIUM MANAGEMENT LLC 34,129 27,004 -20.88 1,009 814 -19.33
2018-08-01 13F-HR COMERICA BANK 6,599 6,609 0.15 222 210 -5.41

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

AstraZeneca plots China robot offensive to counter price cuts

2018-09-19 reuters
WUXI, China/LONDON (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca (AZN.L) aims to move from simply supplying drugs to become a broad healthcare provider in China.

Your Daily Pharma Scoop: Novocure's Mesothelioma Success, Sangamo's Mixed Results, China's First Homegrown Onco Med

2018-09-06 seekingalpha
Discussion: Novocure (NVCR), a midcap biopharma with about $4bn in market capitlization, has seen a tripling of its valuation this year on the back of a slew of positive news. Just about a year ago, its product candidate OPTUNE, already approved in 2011 to treat glioblastoma, saw positive phase 3 results in a trial in newly diagnosed glioblastoma patients, a brain cancer that is notoriously difficult to treat. (0-1)

A watershed moment for China's pharmaceuticals industry, and there's much more to come

2018-09-05 telegraph.co.uk
China’s nascent pharmaceuticals industry has just celebrated a landmark moment. A cancer drug called fruquintinib has become the first home-grown oncology medication ever to be approved by Chinese regulators. In fact, apart from Artemisinin, an anti-malarial, China has never discovered, developed and commercialised a drug of its own. This is a big deal for the country and a watershed moment in China’s path towards becoming a pharmaceuticals powerhouse.

Boost for "made in China" medicine as Chi-Med wins key approval

2018-09-05 reuters
LONDON (Reuters) - Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for “made in China” medicine.

To Get the Latest Drugs, Head to China

2018-08-03 theedgemarkets
(Aug 3): It’s been less than a year since Beijing cut back red tape on drug approvals and already Chinese patients can expect to get some breakthrough medicines before Americans. (7-1)

To Get the Latest Drugs, Head to China - Bloomberg

2018-08-03 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (7-1)

Hutchison China MediTech Ltd (HCM) CEO Christian Hogg on Q2 2018 Results - Earnings Call Transcript

2018-07-27 seekingalpha
Hutchison China MediTech Ltd (NASDAQ:HCM) Q2 2018 Earnings Conference Call July 27, 2018 9:00 AM ET

Hutchison China MediTech Ltd. 2018 Q1 - Results - Earnings Call Slides

2018-07-27 seekingalpha
The following slide deck was published by Hutchison China MediTech Ltd. in conjunction with their 2018 Q1 earnings call.

Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

2018-06-07 seekingalpha
Novocure strengthened its Board of Directors and Abeona Therapeutics received a key analyst thumbs up. Two possible trades are suggested. (627-7)

China weighs new high-tech stock venue in battle with Hong Kong, people say

2018-06-05 scmp
China is expanding efforts to keep its most promising companies from going public in Hong Kong or the US, with officials studying a new trading venue in Shanghai that would have lower thresholds for biotechnology and high-tech firms, people with knowledge of the matter said. (86-0)

CUSIP: 44842L103